24/7 Market News Snapshot 14 May, 2025 – Silo Pharma, Inc. Common Stock (NASDAQ:SILO)

May 14, 2025

DENVER, Colo., 14 May, 2025 (www.247marketnews.com) – (NASDAQ:SILO) are discussed in this article.
Silo Pharma, Inc. (SILO) is currently facing a notable bearish trend, with its shares trading at $0.938 in the pre-market, representing a significant decline of approximately 14.73% from the previous closing price of $1.10. The trading activity has surged, with a volume of 2.30 million shares, reflecting heightened investor engagement and sentiment. This downward movement may indicate investor apprehension or broader market influences, and technical indicators suggest a crucial support level around $0.90. A breach of this level could lead to further losses, prompting traders to closely monitor volume trends and evaluate potential reversals in the short-term outlook for the company.

In a strategic development, Silo Pharma has announced a pivotal collaboration with Frontage Laboratories to conduct a comprehensive 7-day safety and toxicology study of its lead therapeutic candidate, SPC-15. This intranasal prophylactic treatment is being evaluated for its efficacy in addressing post-traumatic stress disorder (PTSD) and aims to enhance the safety profile of the investigational new drug (IND) application currently in progress. Eric Weisblum, CEO of Silo, highlighted the significance of this study, affirming the ambition to bolster data supporting the SPC-15 IND application to the FDA, with plans for submission anticipated within the year.

Concurrently, Silo is advancing a Good Laboratory Practice (GLP)-compliant toxicology and toxicokinetic study of SPC-15, with expected positive outcomes to support the IND submission and enable progression to a first-in-human Phase 1 clinical trial. As an intranasal serotonin 5-HT4 receptor agonist, SPC-15 has emerged as a potential solution for treating stress-related conditions such as PTSD and anxiety. The company retains exclusive global rights to develop and commercialize SPC-15 through its collaboration with Columbia University, reflecting its commitment to addressing significant unmet medical needs in psychiatric care.

Related news for (SILO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.